Jefferies Cuts Numbers on Halozyme Therapeutics (HALO)
Tweet Send to a FriendGet Alerts HALO Hot Sheet
Price: $7.96 -0.25%
Rating Summary:
6 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 0 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade HALO Now!
Jefferies cut estimates and its price target on Halozyme Therapeutics (NASDAQ: HALO) from $10 to $8 after the FDA requested more data on HyQvia.
The firm commented, "Uncertainties surrounding details on FDA's concern of chronic use of HyQvia and requested additional data (& what's required to address the issues) are more concerning than approval delay itself. If the issues are related to rHuPH20 in general (vs. limited to HyQvia itself), it would be more damaging to HALO. Baxter could provide some details on Thursday, Apr 19, 2012 on its 1Q12 earnings call."
The firm cut FY12 EPS from ($0.57) to ($0.58) and FY13 from ($0.51) to ($0.54).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $8.56 yesterday, with a 52 week range of $5.54-$13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm commented, "Uncertainties surrounding details on FDA's concern of chronic use of HyQvia and requested additional data (& what's required to address the issues) are more concerning than approval delay itself. If the issues are related to rHuPH20 in general (vs. limited to HyQvia itself), it would be more damaging to HALO. Baxter could provide some details on Thursday, Apr 19, 2012 on its 1Q12 earnings call."
The firm cut FY12 EPS from ($0.57) to ($0.58) and FY13 from ($0.51) to ($0.54).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $8.56 yesterday, with a 52 week range of $5.54-$13.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Lazard Cuts PT on Aruba (ARUN) to $18; Cisco Pressure Lingers, But Fundamentals Solid
- SunPower (SPWR) Not Worth More than $13/Share, Says Goldman
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Jefferies & Co, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
